Slow-acting insulin preparationsAn aqueous pharmaceutical formulation having an insulin analog, zinc 0.001~0.2mg / ml, preservatives 0.1~5.0mg / ml, and the present invention, etc. The 5.0~100mg / ml less than or equal to 5, the pH of pharmaceutical formulation and comprise a tonicity agent...
For crystallized insulin preparations, shaking the bottle is an important element that the development of slow-acting analogues should eliminate, but the time... HG Hanaire-Broutin - 《Diabetes & Metabolism》 被引量: 90发表: 2005年 Sustained release of insulin from insoluble inhaled particles Conv...
Conclusion: The use of slow-acting-insulin is not inferior to the use of fast-acting-insulin in the management of partially insulin-controlled moderate diabetes in rats. Key words: Diabetes mellitus. Insulin. Rats. DOI: http://dx.doi.org/10.1590/s0102-8650202000700000...
beta subunit (AChRβ1) (CHRNB1; Mm00680412_m1; Life Technologies), delta subunit (AChRδ) (CHRND; Mm00445545_m1; Life Technologies), tumour necrosis factor alpha (TNF-alpha) (Mm00443258_m1; Life Technologies), insulin-like growth factor...
Childhood chronic kidney disease commonly progresses toward end-stage renal failure, largely independent of the underlying disorder, once a critical impair
Slow-acting insulin preparationsAn aqueous pharmaceutical formulation having an insulin analog, zinc 0.001~0.2mg / ml, preservatives 0.1~5.0mg / ml, and the present invention, etc. The 5.0~100mg / ml less than or equal to 5, the pH of pharmaceutical formulation and comprise a tonicity agent...
The invention relates to aqueous pharmaceutical formulations having an insulin analog, said formulations comprising 0.001 to 0.2 mg/ml of zinc, 0.1 to 5.0 mg/ml of a preservative, and 5.0 to 100 mg/ml of an isotonic agent, and the pH value of which is 5 or less. The invention further ...
Also, their preparation, their use for treating diabetes mellitus and a Medicine to treat diabetes mellitus.Claim 1: aqueous Pharmaceutical formulations comprising an insulin Analogue to formula (1) where A0 is Lys or Arg; A5 is ASP, GLN or Glu, ASP Glu or GLN is A15 and A18 is ASP, ...
Rapid- and slow-acting insulins help control diabetesIf the united states' healthcare trend continues on its current course, in 20 years the number of people with diabetes will more than double to 50 million. This dismaying prediction comes from a new report from the Yale Schools of Public ...
On page 559, right column, 3rd paragraph, the first sentence should read:''In this work, two types of insulin were considered: lispro (Eli Lilly and Company, Indianapolis, IN) as the rapid-acting insulin and glargine (Lantus®, sanofi-aventis, Bridgewater, NJ) as the slow-actingF ...